COVID-19’s global spread and resulting impact on all health systems has brought AI/ML tools and technologies front and center to help us navigate and eventually survive the crisis.
Nowhere is this more evident than in clinical development. Ongoing clinical trials have been paused, while many COVID-19 related trials have ramped up at seemingly warp speed. What does this mean for the future of clinical development? What innovations are necessary to get clinical trials and drugs to patients safely and faster in a time of pandemic and the post-pandemic era?
Here’s what the AI in Biopharma Summit Community are talking about
Pharmaceutical companies and clinical research organizations are feeling the effects of the COVID-19 outbreak on the clinical trial life cycle and are likely to incorporate remote ways of working to mitigate disruption
Below is a sample of the timely case studies to be shared at the AI Applications in Biopharma Summit this October 26 and 27 in Boston:
Case study: The need for a modernized drug development model in a pandemic leveraging RWE and advanced analytics
Ülo Palm, MD, Ph.D, Senior Vice President, Digital Sciences, Allergan Pharmaceuticals, Inc. will cover:
- The myth of the value of randomized controlled trials in a pandemic
- How the traditional drug development model leaves patients behind
- Modernizing drug development with an integrated RWE research platform and advanced analytics
- Barriers to overcome with government and regulators